These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Shingleton HM; Soong SJ; Gelder MS; Hatch KD; Baker VV; Austin JM Obstet Gynecol; 1989 Jun; 73(6):1027-34. PubMed ID: 2726106 [TBL] [Abstract][Full Text] [Related]
27. Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the Memorial Sloan-Kettering Cancer Center experience (1972-1981). Lawhead RA; Clark DG; Smith DH; Pierce VK; Lewis JL Gynecol Oncol; 1989 Jun; 33(3):279-82. PubMed ID: 2722049 [TBL] [Abstract][Full Text] [Related]
28. Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. Matsuo K; Mandelbaum RS; Adams CL; Roman LD; Wright JD Gynecol Oncol; 2019 May; 153(2):368-375. PubMed ID: 30792003 [TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer. Tanaka S; Nagase S; Kaiho-Sakuma M; Nagai T; Kurosawa H; Toyoshima M; Tokunaga H; Otsuki T; Utsunomiya H; Takano T; Niikura H; Ito K; Yaegashi N Int J Clin Oncol; 2014 Feb; 19(1):133-8. PubMed ID: 23404487 [TBL] [Abstract][Full Text] [Related]
36. The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Iglesias DA; Westin SN; Rallapalli V; Huang M; Fellman B; Urbauer D; Frumovitz M; Ramirez PT; Soliman PT Gynecol Oncol; 2012 May; 125(2):336-42. PubMed ID: 22261299 [TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of pelvic exenteration for gynecologic malignancies. Moolenaar LR; van Rangelrooij LE; van Poelgeest MIE; van Beurden M; van Driel WJ; van Lonkhuijzen LRCW; Mom CH; Zaal A Gynecol Oncol; 2023 Apr; 171():114-120. PubMed ID: 36870097 [TBL] [Abstract][Full Text] [Related]
38. Robotic or laparoscopic pelvic exenteration for gynecological malignancies: feasible options to open surgery. Dudus L; Minciuna C; Tudor S; Lacatus M; Stefan B; Vasilescu C J Gynecol Oncol; 2024 Mar; 35(2):e12. PubMed ID: 37921597 [TBL] [Abstract][Full Text] [Related]
39. Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies. Angeles MA; Mallet E; Rouanet P; Cabarrou B; Méeus P; Lambaudie E; Foucher F; Narducci F; Loaec C; Gouy S; Guyon F; Marchal F; Gladieff L; Martínez-Gómez C; Migliorelli F; Martinez A; Ferron G Int J Gynecol Cancer; 2020 Feb; 30(2):233-240. PubMed ID: 31796531 [TBL] [Abstract][Full Text] [Related]
40. Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. Matsuo K; Matsuzaki S; Mandelbaum RS; Kanao H; Chang EJ; Klar M; Roman LD; Wright JD Gynecol Oncol; 2021 Apr; 161(1):39-45. PubMed ID: 33402282 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]